Author

Jin-Bo Gou

Observed names: J B Gou, J. Gou, Jinbo Gou

OpenAlex ID: A5057822709

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

2020 · Feng-Cai Zhu, Yu-Hua Li, et al. · The Lancet · 1,410

PDF

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

2020 · Feng-Cai Zhu, Xu-Hua Guan, et al. · The Lancet · 1,238

PDF

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

2021 · Scott A Halperin, Lingyun Ye, et al. · The Lancet · 226

PDF

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

2022 · Jing-Xin Li, Shi-Po Wu, et al. · The Lancet Respiratory Medicine · 169

PDF

Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

2021 · Fengcai Zhu, Pengfei Jin, et al. · Clinical Infectious Diseases · 109

Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized Trial

2022 · Rong Tang, Hui Zheng, et al. · The Lancet Respiratory Medicine · 64

PDF

Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

2023 · Jing-Xin Li, Li-Hua Hou, et al. · The Lancet Infectious Diseases · 61

PDF

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

2022 · Lairun Jin, Rong Tang, et al. · Emerging Microbes & Infections · 30

Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial

2023 · Jun-Dong Wu, Jing-Xin Li, et al. · The Lancet Infectious Diseases · 28

PDF

Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study

2023 · Tao Huang, Sheng Zhang, et al. · The Lancet Respiratory Medicine · 19

PDF

Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial

2023 · Jia-Wei Xu, Bu-Sen Wang, et al. · Emerging Microbes & Infections · 13

PDF

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial

2023 · Peng-Fei Jin, Xi-Ling Guo, et al. · The Lancet Regional Health - Western Pacific · 13

PDF

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

2024 · Chun K. Chew, Ruijie Wang, et al. · npj Vaccines · 12

PDF

Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18–49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study

2024 · Yanxia Wang, Gang Shi, et al. · Vaccines · 9

PDF

Antibody Persistence and Safety through 6 Months after Heterologous Orally Aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously

2022 · Lairun Jin, Rong Tang, et al. · medRxiv · 8

PDF

Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China

2026 · Wei Zhang, Chen Wei, et al. · Emerging Microbes & Infections · 4

PDF

Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults

2023 · Zhili Jin, Jingxuan Wu, et al. · Journal of Infection · 3

Heterologous CoronaVac plus Ad5-nCOV versus homologous CoronaVac vaccination among elderly: a phase 4, non-inferiority, randomized study

2022 · Pengfei Jin, Jingxin Li, et al. · medRxiv · 3

PDF

A protein-based pneumococcal vaccine elicits broad immunity associated with multifunctional antibody responses in humans

2026 · Kaiyi Li, Jinglu Yang, et al. · Journal of Clinical Investigation · 2

PDF

Preliminarily evaluation the safety and immunogenicity of tetanus, reduced diphtheria and acellular pertussis (five components) combined vaccine, adsorbed (Tdcp) in participants aged 6 years and above: a blinded and randomised, and controlled phase I clinical trial

2025 · Xiaoyu Liu, Chen Wei, et al. · Frontiers in Immunology · 2

PDF

Baseline Analysis of Serotype-Specific IgG Antibody Levels for 13-Valent Pneumococcal Conjugate Vaccine in Healthy Chinese Individuals: A Multicenter Retrospective Study

2025 · Gang Shi, Hong Li, et al. · Vaccines · 2

PDF

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial

2024 · Zhiqiang Xie, Jiangjiao Li, et al. · Vaccines · 2

PDF

[A phase Ⅲ clinical trial study on the safety and immunogenicity of ACYW135 group meningococcal conjugate vaccine inoculated in 3 month old infants].

2020 · Z Q Xie, D Y Zhao, et al. · PubMed · 2

[Immunogenicity of group A+C meningococcal polysaccharide conjugate vaccine in infants: A phase Ⅲ clinical trial study].

2022 · L L Huang, X M Ma, et al. · PubMed · 1

Safety and Immunogenicity of Heterologous Boost Immunisation With an Aerosolized Ad5-nCoV After Two-Dose Priming With an Inactivated SARS-CoV-2 Vaccine CoronaVac in Adults: A Randomised, Open-Label, Parallel-Control Trial

2022 · Jing-Xin Li, Shi-Po Wu, et al. · SSRN Electronic Journal · 1

Works count: 37

Citation count: 3,431

H-index: 12

I10-index: 13